Sanofi
SNY
732 hedge funds and large institutions have $12.8B invested in Sanofi in 2024 Q4 according to their latest regulatory filings, with 82 funds opening new positions, 251 increasing their positions, 280 reducing their positions, and 92 closing their positions.
27% more call options, than puts
Call options by funds: $94.5M | Put options by funds: $74.6M
1.29% less ownership
Funds ownership: 22.21% → 20.92% (-1.3%)
3% less funds holding
Funds holding: 758 → 732 (-26)
10% less repeat investments, than reductions
Existing positions increased: 251 | Existing positions reduced: 280
11% less first-time investments, than exits
New positions opened: 82 | Existing positions closed: 92
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
21% less capital invested
Capital invested by funds: $16.3B → $12.8B (-$3.49B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$259M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$127M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$86.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$43.8M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$38.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$391M |
| 2 |
Bank of New York Mellon
New York
|
-$332M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$186M |
| 4 |
BlackRock
New York
|
-$135M |
| 5 |
Millennium Management
New York
|
-$124M |
SNY Hedge Fund Activity: Q4 2024 in Review
732 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q4 2024, worth a combined $12.8B — down 21% from $16.3B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of SNY and 82 opened new positions — a net loss of 10 holders — while 280 trimmed existing stakes and 251 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $259M. The largest seller was Morgan Stanley, cutting an estimated $391M.
- 732 institutional investors held Sanofi (SNY) as of Q4 2024, down from 758 in Q3 2024.
- Funds reported $12.8B of Sanofi stock for Q4 2024, down 21% quarter-over-quarter.
- 82 funds opened new Sanofi positions in Q4 2024 and 92 closed out, a net change of -10 holders.
- The largest Sanofi buyer in Q4 2024 was T. Rowe Price Associates, an estimated $259M added.
- The largest Sanofi seller in Q4 2024 was Morgan Stanley, an estimated $391M sold.
Based on aggregated 13F filings for Q4 2024.